urotoday - the global online community of urologists
urotoday - gu onctoday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of gu oncology and urology.
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-02 | 127.597 |
| 2025-03 | 156.108 |
| 2025-04 | 119.214 |
| Source | Traffic Share |
|---|---|
| search | 61.52% |
| direct | 30.54% |
| referrals | 6.20% |
| social | 1.16% |
| paid referrals | 0.45% |
| 0.10% |
| Region | Percentage |
|---|---|
| United States | 44.21% |
| Japan | 5.84% |
| India | 3.55% |
| IT | 3.38% |
| United Kingdom | 3.04% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| urotoday clinical trials | 116 | 1,160 | $0.00 |
| intra luminal vs extra luminal idc cauti | 4 | 40 | $0.00 |
| de397, targeting mtap-deleted tumors, is in phase 1 trials, indicating a novel approach for this subset of bladder cancer. | 0 | 0 | $0.00 |
| lu-psma | 41 | 410 | $0.00 |
| psmafore urotoday | 19 | 190 | $0.00 |